DENVER — There may be a link between migraine and clinical endocannabinoid deficiency, a speaker said at the American Headache Society’s annual scientific meeting.
“That has really come from this idea that if you measure endocannabinoid lipid levels, from platelets or [cerebrospinal fluid] from migraine patients or those who have medication overuse, they actually have significantly lower levels of circulating endocannabinoid lipids,” Tally Largent-Milnes, PhD, assistant professor of pharmacology at the University of Arizona, said.
Largent-Milnes noted that when comparing